GovWire

Research: ACMD advice on 2-benzyl benzimidazole and piperidine benzimidazolone opioids

Advisory Council On The Misuse Of Drugs

July 18
11:00 2022

ACMD advice on 2-benzyl benzimidazole and piperidine benzimidazolone opioids

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Cover letter from ACMD with advice on benzyl benzimidazole and piperidine benzimidazolone opioids

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This report from the Advisory Council on the Misuse of Drugs (ACMD) describes the use and harms of 2-benzyl benzimidazole (nitazene) opioids (including isotonitazene) and piperidine benzimidazolone opioids (including brorphine).

The report contains recommendations on the classification and scheduling of isotonitazene, brorphine and related substances, following a thorough review of the evidence available and using the expertise of the ACMD Novel Psychoactive Substances Committee (NPSC) members.

The report is a response to 2 separate ministerial commissions on isotonitazene and brorphine asking ACMD to advise on the appropriate classification and scheduling of these compounds under the Misuse of Drugs Act 1971 and associated regulations. This needed to be in line with international controls of those compounds, as

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: